TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06634394: APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Sponsor: Aptevo Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 39 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,036,728

Rescue Site Savings

+$691,152

Unlock Full NCT06634394 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06634394 Rescue Dossier →